MorphoSys AG To Acquire Constellation Pharmaceuticals M&A Call Transcript
Welcome, ladies and gentlemen. My name is Julia Neugebauer, Senior Director of Investor Relations. It's my pleasure to welcome you to our (technical difficulty) Constellation Pharmaceuticals and our strategic funding partnership with Royalty Pharma, which we announced earlier this morning.
You'll find a brief presentation in the Media and Investors section on our website, morphosys.com, under the section MorphoSys Events or by visiting our transaction web page at morphosys-constellation-royaltypharma.com.
Before we begin, I'd like to remind you on Slide 2 that some of the statements we make during the call are forward-looking statements, including statements regarding our expectations for the commercialization of our products and our development plans as well as the development plans of our collaboration partners. These forward-looking statements are subject to a number of risks and uncertainties that may cause our actual results to differ materially, including those described in MorphoSys 20-F and annual
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |